Rocket Pharmaceuticals, Inc. (RCKT) earnings
RCKT earnings moved a median of -2.76% by the close. Quarterly and annual RCKT reports and results, each read against the price at its own news timestamp. Back to the RCKT overview →
19 measured RCKT earnings events.
Where these RCKT earnings landedvs 19 measured RCKT earnings reactions
| Middle 50% of RCKT earnings reactions | -4.13% to +0.87% |
|---|---|
| Median reaction (to close) | -2.76% |
| Measured reactions | 19 |
Point-in-time · zero look-ahead
Half of the 19 RCKT earnings events with a measured close landed between -4.13% and +0.87%; 32% closed up.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Form 10-Q ROCKET PHARMACEUTICALS, For: Mar 31 | SEC filing · Form 10-Q | +3.58% | -3.71% | |
| Rocket Pharmaceuticals Reports First Quarter 2026 Financial Results and Highlights Recent Progress | Press release | +3.58% | -3.71% | |
| Form 10-K ROCKET PHARMACEUTICALS, For: Dec 31 | SEC filing · Form 10-K | +10.46% | +9.15% | |
| Form 10-Q ROCKET PHARMACEUTICALS, For: Sep 30 | SEC filing · Form 10-Q | -4.14% | -2.76% | |
| Rocket Pharmaceuticals Reports Third Quarter 2025 Financial Results and Highlights Recent Progress | Press release | -4.14% | -2.76% | |
| Form 10-Q ROCKET PHARMACEUTICALS, For: Jun 30 | SEC filing · Form 10-Q | -5.03% | -10.06% | |
| Rocket Pharmaceuticals Reports Second Quarter 2025 Financial Results and Highlights Recent Progress | Press release | -5.03% | -10.06% | |
| Form 10-Q ROCKET PHARMACEUTICALS, For: Mar 31 | SEC filing · Form 10-Q | +2.96% | +0.87% | |
| Rocket Pharmaceuticals Reports First Quarter 2025 Financial Results and Highlights Recent Progress | Press release | +2.96% | +0.87% | |
| Form 10-K ROCKET PHARMACEUTICALS, For: Dec 31 | SEC filing · Form 10-K | -3.98% | -1.05% | |
| Form 10-Q ROCKET PHARMACEUTICALS, For: Sep 30 | SEC filing · Form 10-Q | +1.23% | +0.93% | |
| Rocket Pharmaceuticals Reports Third Quarter 2024 Financial Results and Highlights Recent Progress | Press release | +1.23% | +0.93% | |
| Form 10-Q ROCKET PHARMACEUTICALS, For: Jun 30 | SEC filing · Form 10-Q | -1.72% | -7.13% | |
| Rocket Pharmaceuticals Reports Second Quarter 2024 Financial Results and Highlights Recent Progress | Press release | -5.23% | -3.45% | |
| Form 10-Q ROCKET PHARMACEUTICALS, For: Mar 31 | SEC filing · Form 10-Q | -1.18% | -1.42% | |
| Rocket Pharmaceuticals Reports First Quarter 2024 Financial Results and Highlights Recent Progress | Press release | -1.80% | -0.09% | |
| Form 10-K ROCKET PHARMACEUTICALS, For: Dec 31 | SEC filing · Form 10-K | +0.59% | -4.54% | |
| Form 10-Q ROCKET PHARMACEUTICALS, For: Sep 30 | SEC filing · Form 10-Q | -1.91% | -6.59% | |
| Rocket Pharmaceuticals Reports Third Quarter 2023 Financial Results and Highlights Recent Progress | Press release | -0.91% | +1.09% |
Keep exploring
More RCKT: analyst actions → · SEC filings → · RCKT overview →
Other Healthcare names and their earnings
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| IMMUNOMEDICS (IMMU) | 1,213 | -0.08% | 45% |
| Biogen Inc. (BIIB) | 1,208 | -0.01% | 49% |
| Insulet Corporation (PODD) | 1,198 | +0.14% | 55% |
| Invacare Corporation (IVC) | 1,193 | 0.00% | 49% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not. These are each name’s all-news baseline, not its earnings — that is what the link opens.